Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT321 + mFOLFIRINOX in adjuvant pancreatic cancer
NCT06069778Phase 2Terminated
- Sponsor
- BioNTech SE
- Start
- Mar 2024
- Primary completion
- Sep 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of CA19-9-targeting monoclonal antibody in pancreatic ductal adenocarcinoma (PDAC), sponsored by BioNTech SE. Started Mar 2024; status: terminated.
02
Drugs
CA19-9-targeting monoclonal antibody
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06069778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06069778.